Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Abatacept Active Treatment1件: Abatacept1件: Abatacept 💬2件: CD80,
CD86 💬		13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 50 💬
2Abatacept Delayed-Onset Treatment1件: Abatacept1件: Abatacept 💬2件: CD80,
CD86 💬		13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 50 💬
3Active Investigational Treatment ENT-01----1件: 6 💬
4Active Treatment Group 7% Hypertonic Saline----1件: 299 💬
5Baclofen (baclofen Tab. 10mg) treatment1件: Baclofen1件: Baclofen 💬2件: GABBR1,
GABBR2 💬		7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬1件: 70 💬
6Baricitinib treatment1件: Baricitinib1件: Baricitinib 💬2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
7Baseline Treatment----1件: 13 💬
8BDMARD treatment----1件: 271 💬
9Best Medical Treatment----1件: 6 💬
10Best médical treatment----1件: 6 💬
11Bisphosphonate treatment----2件: 113, 299 💬
12Botulism Toxin Treatment----1件: 161 💬
13Break in L-carnitine treatment1件: Levocarnitine1件: Levocarnitine 💬--1件: 316 💬
14Chinese herbal medicine treatment----1件: 6 💬
15Classic DMARDs treatment group----1件: 46 💬
16Clobetasol Propionate cream treatment2件: Clobetasol,
Clobetasol propionate		2件: Clobetasol propionate ,
Clobetasol 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
17Clopidogrel treatment1件: Clopidogrel3件: Clopidogrel ,
Clopidogrel hydrochloride ,
Clopidogrel besilate 💬		1件: P2RY12 💬1件: Platelet activation 💬1件: 51 💬
18Combination Product: Active treatment with dual therapy----1件: 2 💬
19Conventional treatment----1件: 97 💬
20Conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)1件: Mesalazine1件: Mesalamine 💬--2件: 96, 97 💬
21Corticosteroid treatment (Methylprednisolone or prednisolone)2件: Methylprednisolone,
Prednisolone		2件: Methylprednisolone ,
Prednisolone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 64 💬
22Crysvita (burosumab-twza) Treatment1件: Burosumab1件: Burosumab 💬1件: FGF23 💬11件: Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬1件: 238 💬
23Current lipid-lowering treatment----1件: 79 💬
24Current treatment of AL-CM----1件: 28 💬
25Detoxifying agents for antineoplastic treatment----2件: 299, 337 💬
26Disease modifying treatment (DMT)----1件: 13 💬
27Disease modifying treatments----1件: 3 💬
28Dopamine agonist treatment1件: Dopamine1件: Dopamine 💬5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 74 💬
29Drug treatment----3件: 51, 74, 271 💬
30ERA as specific PAH treatment----1件: 86 💬
31Etanercept Treatment1件: Etanercept1件: Etanercept 💬2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
32Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 222 💬
33Fibrate treatment----1件: 160 💬
34Foliglurax 10 mg (treatment A)1件: Foliglurax---1件: 6 💬
35Foliglurax 30 mg (treatment B)1件: Foliglurax---1件: 6 💬
36From August 2020 'no additional treatment'----1件: 51 💬
37Gabapentin (neurontin® capsule 300mg) treatment1件: Gabapentin1件: Gabapentin 💬5件: CACNA2D1,
CACNA2D2,
CACNA2D3,
CACNA2D4,
SLC6A1 💬		9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬1件: 70 💬
38GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made.1件: Somatotropin---1件: 193 💬
39Glucocorticoid Treatment----1件: 41 💬
40Golimumab treatment optimization.1件: Golimumab1件: Golimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97 💬
41HAESCs treatment----1件: 6 💬
42HCQ/CQ and CAB combined treatment----1件: 74 💬
43Herbal treatment (SA100)----1件: 97 💬
44Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment1件: Xenon2件: Xenon ,
Xenon Xe 133 💬		--1件: 85 💬
45Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment1件: Xenon2件: Xenon ,
Xenon Xe 133 💬		--1件: 85 💬
46Immunosuppressive treatment----1件: 66 💬
47Immunosuppressive treatment (eg, rituximab)1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 64 💬
48In double-blind phase: treatment with tofacitinib1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 107 💬
49In open-label phase: treatment with tofacitinib1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 107 💬
50Interferon beta treatment to add-on atorvastatin treatment2件: Atorvastatin,
Human interferon beta		1件: Atorvastatin 💬1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 13 💬
51IV treatment with IGSC, 10%----1件: 65 💬
52Lapaquistat acetate and current lipid-lowering treatment2件: Acetate,
Lapaquistat		---1件: 79 💬
53Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP5件: Dapsone,
Mycophenolate mofetil,
Mycophenolic acid,
Prednisolone,
Triamcinolone		5件: Triamcinolone ,
Prednisolone ,
Dapsone ,
Mycophenolate mofetil ,
Mycophenolic acid 💬		3件: IMPDH1,
IMPDH2,
NR3C1 💬		5件: Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬1件: 162 💬
54Lumacaftor-Ivacaftor treatment2件: Ivacaftor,
Lumacaftor		2件: Ivacaftor ,
Lumacaftor 💬		1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299 💬
55Metformin treatment1件: Metformin1件: Metformin 💬2件: PRKAA1,
PRKAA2 💬		20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬1件: 46 💬
56Methotrexate treatment1件: Methotrexate1件: Methotrexate 💬2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬2件: 41, 46 💬
57MK0812 / Duration of Treatment: 12 Weeks----1件: 46 💬
58MSC treatment----1件: 49 💬
59MSC treatment 01----1件: 96 💬
60MSC treatment 02----1件: 96 💬
61Natalizumab treatment1件: Natalizumab1件: Natalizumab 💬1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13 💬
62Nifurtimox-Eflronithine Combination Treatment (NECT)1件: Nifurtimox1件: Nifurtimox 💬--1件: 65 💬
63Nusinersen Treatments1件: Nusinersen1件: Nusinersen 💬1件: SMN2 💬-1件: 3 💬
64OC oral solution treatment A----1件: 6 💬
65OC oral solution treatment B----1件: 6 💬
66OC oral solution treatment C----1件: 6 💬
67OC oral solution treatment D----1件: 6 💬
68Only 1 arm: treatment with MSC-AFP----1件: 96 💬
69Optimized antiparkinsonian treatment----1件: 6 💬
70Optimized Medical Treatment----1件: 6 💬
71Optimized oral treatment----1件: 6 💬
72Oral anticoagulant treatment----1件: 86 💬
73Other Parkinson's Disease treatments----1件: 6 💬
74Perfusion of treatment Ocrelizumab1件: Ocrelizumab1件: Ocrelizumab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
75Perfusion of treatment Rituximab1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
76Pharmacologic approaches to glycemic treatment----1件: 298 💬
77Plasma from healthy young people treatment + Riluzole1件: Riluzole1件: Riluzole 💬14件: GRIA1,
GRIA2,
GRIA3,
GRIA4,
GRIK1,
GRIK2,
GRIK3,
GRIK4,
GRIK5,
GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		23件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬1件: 2 💬
78PPI treatment----1件: 299 💬
79Prednisone and ustekinumab treatment2件: Prednisone,
Ustekinumab		2件: Prednisone ,
Ustekinumab 💬		4件: IL12A,
IL12B,
IL23A,
NR3C1 💬		29件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Neuroactive ligand-receptor interaction, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬1件: 41 💬
80Prednisone treatment1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 41 💬
81Propranolol treatment1件: Propranolol1件: Propranolol 💬3件: ADRB1,
ADRB2,
ADRB3 💬		12件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 227 💬
82Regular treatment----1件: 97 💬
83Routine Treatment of CD----1件: 96 💬
84SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)----1件: 65 💬
85SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)----1件: 65 💬
86Simvastatin treatment for 28 days1件: Simvastatin1件: Simvastatin 💬1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 299 💬
87Standard of Care Treatment----3件: 53, 245, 246 💬
88Standard Steroid Treatment----1件: 85 💬
89Standard treatment with a conventional drug----1件: 13 💬
90Standard-of-care treatment----1件: 49 💬
91Standrd of Care treatment----1件: 64 💬
92Study treatment PPI----1件: 166 💬
93Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)3件: Aldosterone,
Angiotensin II,
Calcium (Restoration Treatment)		3件: Angiotensin II ,
Angiotensin II ,
Aldosterone 💬		3件: AGTR1,
AGTR2,
NR3C2 💬		17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222 💬
94Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)1件: Human immunoglobulin G---1件: 11 💬
95Systemic non-biological treatments----2件: 46, 271 💬
96The Comprehensive Treatment Regimen of Traditional Chinese Medicine----1件: 222 💬
97The Standard Steroid Treatment, Plasma Exchange and rituximab1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 85 💬
98Time delay treatment of botulinum toxin----1件: 149 💬
99TL011, anti CD20, for the treatment of rheumatoid arthritis----1件: 46 💬
100Tocilizumab treatment1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
101Top down treatment if patient at high risk----2件: 96, 97 💬
102Traditional treatment of CGD and TB----1件: 65 💬
103Traditional treatments----1件: 97 💬
104Treatment----2件: 41, 299 💬
105Treatment A----2件: 34, 46 💬
106Treatment Algorithm A----1件: 97 💬
107Treatment Algorithm B----1件: 97 💬
108Treatment Algorithm C----1件: 97 💬
109Treatment as Usual (TAU)----1件: 85 💬
110Treatment B----2件: 34, 46 💬
111Treatment BX1514M----1件: 58 💬
112Treatment C----2件: 34, 46 💬
113Treatment D----1件: 34 💬
114Treatment defined only by active substance----1件: 50 💬
115Treatment I----1件: 46 💬
116Treatment II----1件: 46 💬
117Treatment III----1件: 46 💬
118Treatment of MTX----1件: 46 💬
119Treatment of MTX and HCQ----1件: 46 💬
120Treatment of MTX and TwHF----1件: 46 💬
121Treatment of TCM----1件: 46 💬
122Treatment of TwHF----1件: 46 💬
123Treatment Phase Group 4----1件: 113 💬
124Treatment systemic therapy (prednisone)1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
125Treatment taken----1件: 113 💬
126Treatment vs control bread----1件: 97 💬
127Treatment with Adalimumab1件: Adalimumab1件: Adalimumab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96 💬
128Treatment with azathioprin----1件: 95 💬
129Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor4件: Elexacaftor,
Ivacaftor,
Lumacaftor,
Tezacaftor		4件: Ivacaftor ,
Lumacaftor ,
Tezacaftor ,
Elexacaftor 💬		1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299 💬
130Treatment with mycophenolat mofetil----1件: 95 💬
131Treatment with polyethylene glycol (Macrogol 4000)1件: Polyethylene glycol1件: Polyethylene glycol 3350 💬--1件: 299 💬
132Treatment with systemic therapy (doxycycline)1件: Doxycycline2件: Doxycycline ,
Doxycycline 💬		--1件: 162 💬
133Treatment with systemic therapy (methotrexate)1件: Methotrexate1件: Methotrexate 💬2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 162 💬
134Treatment with systemic therapy (prednisone)1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162 💬
135Treatment with topical superpotent corticosteroid therapy----1件: 162 💬
136Untreated to atorvastatin treatment1件: Atorvastatin1件: Atorvastatin 💬1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 13 💬
137Usual dopaminergic per os treatment----1件: 6 💬
138Vancomycin Pre-Treatment1件: Vancomycin1件: Vancomycin 💬--1件: 97 💬
139Viral load driven treatment interruption----1件: 265 💬